JP2006515744A5 - - Google Patents

Download PDF

Info

Publication number
JP2006515744A5
JP2006515744A5 JP2004541534A JP2004541534A JP2006515744A5 JP 2006515744 A5 JP2006515744 A5 JP 2006515744A5 JP 2004541534 A JP2004541534 A JP 2004541534A JP 2004541534 A JP2004541534 A JP 2004541534A JP 2006515744 A5 JP2006515744 A5 JP 2006515744A5
Authority
JP
Japan
Prior art keywords
mhc class
epitope
presenting
key
terminal element
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004541534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006515744A (ja
Filing date
Publication date
Priority claimed from US10/245,871 external-priority patent/US20030235594A1/en
Priority claimed from US10/253,286 external-priority patent/US7179645B2/en
Application filed filed Critical
Priority claimed from PCT/US2003/028574 external-priority patent/WO2004030616A2/en
Publication of JP2006515744A publication Critical patent/JP2006515744A/ja
Publication of JP2006515744A5 publication Critical patent/JP2006515744A5/ja
Pending legal-status Critical Current

Links

JP2004541534A 2002-09-17 2003-09-12 Ｉｉ−Ｋｅｙ／抗原性エピトープハイブリッドペプチドワクチン Pending JP2006515744A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/245,871 US20030235594A1 (en) 1999-09-14 2002-09-17 Ii-Key/antigenic epitope hybrid peptide vaccines
US10/253,286 US7179645B2 (en) 2002-09-24 2002-09-24 Ii-Key/antigenic epitope hybrid peptide vaccines
PCT/US2003/028574 WO2004030616A2 (en) 2002-09-17 2003-09-12 Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES

Publications (2)

Publication Number Publication Date
JP2006515744A JP2006515744A (ja) 2006-06-08
JP2006515744A5 true JP2006515744A5 (enExample) 2007-10-18

Family

ID=32072825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004541534A Pending JP2006515744A (ja) 2002-09-17 2003-09-12 Ｉｉ−Ｋｅｙ／抗原性エピトープハイブリッドペプチドワクチン

Country Status (5)

Country Link
EP (1) EP1556072B1 (enExample)
JP (1) JP2006515744A (enExample)
AU (1) AU2003294220A1 (enExample)
CA (1) CA2499123A1 (enExample)
WO (1) WO2004030616A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
EP2332971B1 (en) * 2004-06-17 2016-02-17 MannKind Corporation Epitope analogs
JP5222134B2 (ja) * 2005-06-15 2013-06-26 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション Ｈｅｒ−２ペプチド
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
JP2012050440A (ja) * 2011-09-16 2012-03-15 Chiba Univ ヒトＴｈ１／Ｔｈ２分化誘導の評価方法
MX2015005636A (es) 2012-10-30 2015-11-16 Univ Monash Moléculas inmunoterapéuticas novedosas y sus usos.
EP4710935A2 (en) * 2013-09-25 2026-03-18 Aravax Pty Ltd Novel immunotherapeutic composition and uses thereof
DK3388075T5 (da) * 2015-03-27 2024-09-23 Immatics Biotechnologies Gmbh Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
SG11201808710UA (en) * 2016-04-19 2018-11-29 Imcyse Sa Novel immunogenic cd1d binding peptides
CN108129558B (zh) * 2017-12-21 2021-10-12 中国医学科学院北京协和医院 一种桦树花粉主要致敏蛋白Bet v 8的提取和分离纯化方法及应用
US20230000908A1 (en) * 2019-09-11 2023-01-05 Ohio State Innovation Foundation Engineered cells and uses thereof
WO2023240295A2 (en) * 2022-06-10 2023-12-14 Ayass Bioscience Llc Food allergen processing and desensitization by aptamers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
JPH07119760B2 (ja) 1984-07-24 1995-12-20 コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション ミモトープを検出または決定する方法
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5194425A (en) 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
ES2075196T3 (es) 1989-02-17 1995-10-01 Chiron Mimotopes Pty Ltd Metodo para el uso y la sintesis de peptidos.
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
WO1991006658A2 (en) 1989-10-24 1991-05-16 Cetus Corporation Infective protein delivery system
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
JP3523252B2 (ja) 1990-11-21 2004-04-26 ホウテン ファーマシューティカルズ インコーポレイテッド 等モル多種オリゴマー混合物、特にオリゴペプチド混合物の合成
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
AU671971B2 (en) 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
US5679527A (en) 1992-03-25 1997-10-21 Antigen Express, Inc. Modification of polypeptide structure
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5559028A (en) 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
EP0726941B1 (en) 1993-08-06 2002-04-03 Epimmune Inc. Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
US5874214A (en) 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
US5910300A (en) 1995-11-01 1999-06-08 Bracco Research S.A. Amphiphilic linkers for coupling administrable diagnostically or physiologically active agents and bioselective targeting compounds
WO1997049430A1 (en) 1996-06-26 1997-12-31 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response

Similar Documents

Publication Publication Date Title
ES2279625T3 (es) Compuesto y procedimiento para la prevencion y/o el tratamiento de la alergia.
US10772934B2 (en) Highly active polypeptides and methods of making and using the same
US5580563A (en) Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
JP2006515744A5 (enExample)
Kaumaya et al. Peptide vaccines incorporating a ‘promiscuous’ T‐cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity
JP5751741B2 (ja) 免疫原性組成物および使用法
JP3802049B2 (ja) Ｈｉｖに対する中和性抗体および細胞障害性ｔリンパ球を誘発する複合合成ペプチド構築物
JPH04502760A (ja) エイズの診断，予防および治療に有効な新規ｈｉｖ蛋白質およびペプチド
JP2020506690A5 (enExample)
JP2006020648A5 (enExample)
JP2003529319A (ja) ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
JP2001502658A (ja) 非樹状中心骨格ペプチド担体
JPH09505559A (ja) 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
RU2337922C9 (ru) ИЗОЛИРОВАННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ НЕЙТРАЛИЗУЮЩЕГО ЭПИТОПА БЕЛКА p17 ВИРУСА ВИЧ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ВАКЦИН, А ТАКЖЕ НЕЙТРАЛИЗУЮЩИЕ АНТИ-p17-АНТИТЕЛА, СПЕЦИФИЧЕСКИ РАСПОЗНАЮЩИЕ УКАЗАННЫЙ НЕЙТРАЛИЗУЮЩИЙ ЭПИТОП
CN1054772A (zh) 合成多肽
JPH07506374A (ja) う蝕予防用合成ペプチドワクチン
US20030152581A1 (en) Compound and method for the prevention and/or the treatment of allergy
Dakappagari et al. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T‐cell responses in HLA‐A* 201 mice
Ferru et al. Analysis of the immune response elicited by a multiple antigen peptide (MAP) composed of two distinct protective antigens derived from the parasite Schistosoma mansoni
ES2322253T3 (es) Utilizacion de mezclas de lipopeptidos para la fabricacion de vacunas.
JPH07505878A (ja) Ｈｉｖエンベロープ糖タンパク質から誘導された合成ポリペプチド
AU733234B2 (en) Conjugated peptides, immunological reagent containing same and use thereof for treatment of immunological disorders
CN100387616C (zh) 获得可增强特异交叉反应性的抗原结构的方法
JPS58222031A (ja) 合成ワクチン
WO2005034842A2 (en) Peptides useful as hiv fusion inhibitors